Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 1,743 trials

Severe Autoimmune Diseases: CD19-targeted CAR T Cell Therapy

We are testing a new CAR T cell treatment for individuals with severe autoimmune diseases that haven't responded to other therapies. The goal is to see if this approach is safe and how well it works.

Idiopathic Inflammatory MyopathyRheumatoid ArthritisSystemic Sclerosis>2 yearsSafety phase (I)Infectious DiseasesRheumatology

Mucopolysaccharidosis Type II: DNL310 Treatment Study

We are investigating the long-term safety and effects of DNL310 in patients with MPS II. This study looks at how well the treatment works for cognitive and physical development.

Hunter's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNeurology

Endometrial Cancer: Olaparib Maintenance Therapy

We are studying whether olaparib can help prevent cancer recurrence in patients with p53abn endometrial cancer after they receive chemoradiation. This trial compares olaparib treatment to observation alone.

p53abn HREC Patients Post-Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsOncology

Cardiovascular Collapse: Vasopressor Use During Intubation

We are studying whether giving vasopressors before intubation helps prevent cardiovascular collapse in critically ill adults. This research aims to improve safety during a critical medical procedure.

Critical Illness>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Locally Advanced NSCLC: Alectinib vs. Durvalumab

We are studying whether alectinib or entrectinib is more effective than durvalumab for patients with advanced non-small cell lung cancer who have not progressed after initial treatment. The trial also looks at quality of life and safety for participants.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Geographic Atrophy: Tinlarebant Treatment Study

We are exploring whether Tinlarebant can slow the growth of lesions in people with geographic atrophy and improve their vision. This study compares the new treatment to a placebo to assess its effectiveness.

Geographic Atrophy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Ectopic Pregnancy: Mifepristone and Letrozole vs. Methotrexate

We are studying whether a new combination treatment is as effective as the standard medication for ectopic pregnancy. This trial will also look at side effects and the need for further medical interventions.

Ectopic Pregnancy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics

Progressive Glioblastoma: Perampanel Treatment Study

We are studying whether the medication Perampanel can help reduce tumor growth in patients with progressive glioblastoma before surgery. This trial also looks at quality of life and cognitive function to see how the treatment affects patients.

Progressive Glioblastoma>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyOncology

Graft-versus-Host Disease: MC0518 Treatment for Kids

We are studying a new treatment called MC0518 for children with steroid-refractory acute graft-versus-host disease after stem cell transplant. The goal is to see if it works better than the best available therapy.

Steroid Refractory Acute Graft Versus Host Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

DS-1103a: New Combination Therapy Study

We are testing a new combination therapy for patients with specific health conditions. This study aims to understand its safety and effectiveness in humans for the first time.

HER2 Positive Breast Cancer>2 yearsSafety phase (I)Oncology

Nitroglycerin for Esophageal Food Impaction

We are studying whether nitroglycerin can help relieve food impaction in the esophagus. This trial aims to see if it is an effective treatment for those who have trouble swallowing.

Esophageal Food Impaction>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyOtolaryngology

Prostate Cancer: RO7656594 Treatment Study

We are evaluating a new medication for patients with advanced or metastatic prostate cancer. The study focuses on its safety and how the body handles the drug.

Advanced or Metastatic Prostate Cancer>2 yearsSafety phase (I)Oncology

Growth Hormone Deficiency: LUM-201 Treatment Study

We are monitoring the long-term safety of LUM-201 in children with idiopathic growth hormone deficiency. This study also looks at how the treatment affects growth and related health markers.

Idiopathic Growth Hormone Deficiency>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics

Anifrolumab for Polymyositis and Dermatomyositis

We are studying whether Anifrolumab can improve muscle strength and reduce corticosteroid use in adults with polymyositis and dermatomyositis compared to a placebo.

Polymyositis and Dermatomyositis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Breast Cancer Surgery: ICG Imaging Study

We are exploring how a special imaging technique using ICG dye can help surgeons evaluate cancer margins during breast-conserving surgery. This study aims to find the best timing and dose for the dye to improve surgical outcomes.

Early Invasive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

[18F]PSMA-1007 PET/CT Imaging for Prostate Cancer

We are studying how well a new imaging method detects cancer spread in patients with newly diagnosed high-risk prostate cancer. This could help improve diagnosis and treatment planning.

Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Guselkumab for Crohn's Disease Healing

We are studying whether guselkumab can help heal the intestinal wall in patients with Crohn's disease. This research aims to find out how effective it is over 48 weeks.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Advanced Prostate Cancer: JNJ-87189401 and JNJ-78278343

We are exploring the safety of a new combination of medications for patients with advanced prostate cancer. This study aims to find out how well these drugs work together.

Advanced Prostate Cancer>2 yearsSafety phase (I)Oncology

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Primary Biliary Cholangitis: Bezafibrate Treatments

We are studying the effects of two doses of bezafibrate in patients with primary biliary cholangitis who aren't responding well to current therapy. The goal is to see if these treatments can improve symptoms and liver health.

Primary Biliary Cholangitis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyHepatology